drugset / Trial / NCT02806505
HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with Chronic Hepatitis C (CHC) who have End-Stage Renal Disease (ESRD) and were undergoing hemodialysis.
Timeline
- Start
- 2004-06
- Primary completion
- 2007-08
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 90 ug | Subcutaneous |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 135 ug | Subcutaneous |